Please login to the form below

Not currently logged in
Email:
Password:

f-star wins €15m investment

Antibody specialist f-star secures funding from existing investors and adds new members to its supervisory board

f-star, a company developing antibody-based products, has secured €15m of new financing.

The investment initiative was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star's existing investors, Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures and MP Healthcare Venture Management, also participated in the round.

As a result of the financing SR One partner Dr Deborah Harland and Dr Axel Polack of TVM Capital will join f-star's supervisory board.

Harland said: "f-star has shown that its Modular Antibody Technology platform can generate multiple high affinity biotherapeutics against targets of varying precedence and novelty in both single- and bi-specific formats.

"We believe the platform has the potential to generate numerous novel differentiated biologics with advanced efficacy, tissue penetration and targeting capabilities compared to traditional antibodies and are excited to be part of the next stage of the company's development," she added.

13th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics